Despite the proven therapeutic potential of irisin in kidney disease, the intravenous infusion of irisin is hindered by its chemical and physical instabilities within the circulation, resulting in a short half‐life.[14] Moreover, intrinsic characteristics, such as decreased membrane permeability and limited organ‐specific targeting, contribute to its suboptimal therapeutic efficacy. This evidence concerns the gene FNDC5 and kidney disorder.